A historical perspective on ACE2 in the COVID-19 era
J Hum Hypertens
.
2021 Oct;35(10):935-939.
doi: 10.1038/s41371-020-00459-3.
Epub 2020 Dec 14.
Authors
Vivek Bhalla
1
2
3
,
Catherine A Blish
4
5
6
,
Andrew M South
7
8
9
Affiliations
1
Stanford Hypertension Center, Stanford University School of Medicine, Stanford, CA, USA. vbhalla@stanford.edu.
2
Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA. vbhalla@stanford.edu.
3
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. vbhalla@stanford.edu.
4
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
5
Division of Infectious Diseases and Geographical Medicine, Stanford University School of Medicine, Stanford, CA, USA.
6
Chan Zuckerberg Biohub, San Francisco, CA, USA.
7
Section of Nephrology, Department of Pediatrics, Brenner Children's Hospital, Wake Forest School of Medicine, Winston Salem, NC, USA.
8
Department of Surgery-Hypertension and Vascular Research, Wake Forest School of Medicine, Winston Salem, NC, USA.
9
Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston Salem, NC, USA.
PMID:
33318644
PMCID:
PMC7735396
DOI:
10.1038/s41371-020-00459-3
No abstract available
Publication types
Review
MeSH terms
Angiotensin-Converting Enzyme 2*
COVID-19*
Humans
Renin-Angiotensin System
Substances
ACE2 protein, human
Angiotensin-Converting Enzyme 2
Grants and funding
K23 HL148394/HL/NHLBI NIH HHS/United States
L40 HL148910/HL/NHLBI NIH HHS/United States
R01 HL146818/HL/NHLBI NIH HHS/United States